Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-Pola-Glo in Previously Untreated Aggressive B-cell Lymphoma
NCT05798156Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of glofitamab, polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), aggressive B-cell lymphoma, sponsored by Institut für Klinische Krebsforschung. Started Mar 2023; status: active, not recruiting.
02
Drugs
glofitamabpolatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT05798156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798156.